{"id":"tpc-chemotherapy","safety":{"commonSideEffects":[{"rate":"20-40%","effect":"Neutropenia"},{"rate":"10-30%","effect":"Thrombocytopenia"},{"rate":"20-40%","effect":"Anemia"},{"rate":"50-70%","effect":"Nausea and vomiting"},{"rate":"30-50%","effect":"Diarrhea"}]},"_chembl":{"chemblId":"CHEMBL2070025","moleculeType":"Small molecule","molecularWeight":"376.41"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"TPC chemotherapy works by inhibiting the enzymes responsible for DNA replication, leading to cell death in rapidly dividing cancer cells. This results in the slowing or stopping of cancer cell growth and proliferation. The exact molecular targets of TPC chemotherapy are not well-defined, but it is thought to affect multiple pathways involved in DNA replication and repair.","oneSentence":"TPC chemotherapy targets rapidly dividing cancer cells by interfering with their DNA replication.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:39:29.227Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic non-small cell lung cancer, PD-L1 positive"},{"name":"Metastatic triple-negative breast cancer"}]},"trialDetails":[{"nctId":"NCT06841354","phase":"PHASE3","title":"A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-03-16","conditions":"Triple Negative Breast Neoplasms","enrollment":1000},{"nctId":"NCT06966700","phase":"PHASE3","title":"A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-06-30","conditions":"Breast Neoplasms, Triple Negative Breast Neoplasms, HR Low-Positive/HER2-Negative Breast Neoplasms","enrollment":2400},{"nctId":"NCT06312176","phase":"PHASE3","title":"A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-04-14","conditions":"Breast Neoplasms","enrollment":1200},{"nctId":"NCT06524544","phase":"PHASE3","title":"A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan Versus Standard of Care in the Treatment of Advanced Urothelial Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-12-02","conditions":"Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Unresectable Urothelial Carcinoma","enrollment":320},{"nctId":"NCT07173751","phase":"PHASE3","title":"ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer","status":"RECRUITING","sponsor":"BioNTech SE","startDate":"2025-10-30","conditions":"Breast Neoplasms","enrollment":558},{"nctId":"NCT07362979","phase":"PHASE2","title":"Toripalimab Combined With Different Platinum-Based Induction Chemotherapy Regimens for Locally Advanced Nasopharyngeal Carcinoma","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2026-03-12","conditions":"Nasopharyngeal Cancinoma (NPC)","enrollment":243},{"nctId":"NCT06797635","phase":"PHASE2","title":"Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-03-20","conditions":"Breast Neoplasms, Breast Cancer","enrollment":372},{"nctId":"NCT07461454","phase":"PHASE3","title":"YL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"MediLink Therapeutics (Suzhou) Co., Ltd.","startDate":"2026-03-10","conditions":"Locally Advanced or Metastatic Breast Cancer","enrollment":376},{"nctId":"NCT06099769","phase":"PHASE2","title":"A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2023-10-18","conditions":"Metastatic Breast Cancer","enrollment":201},{"nctId":"NCT06829199","phase":"PHASE2","title":"A Clinical Study of Boserolimab (MK-5890) With Pembrolizumab and Chemotherapy in People With Early Triple-Negative Breast Cancer (MK-5890-003)","status":"WITHDRAWN","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-03-26","conditions":"Early Triple Negative Breast Cancer","enrollment":""},{"nctId":"NCT04639986","phase":"PHASE3","title":"Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2020-11-23","conditions":"Metastatic Breast Cancer","enrollment":331},{"nctId":"NCT06486441","phase":"PHASE3","title":"Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2024-08-28","conditions":"Endometrial Cancer","enrollment":640},{"nctId":"NCT05494190","phase":"NA","title":"The Management of Metastatic Neck Nodes in N2/3 Hypopharyngeal Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"Eye & ENT Hospital of Fudan University","startDate":"2022-11-01","conditions":"Hypopharyngeal Carcinoma","enrollment":111},{"nctId":"NCT06081959","phase":"PHASE3","title":"Study of SKB264 for Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast Cancer","status":"RECRUITING","sponsor":"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.","startDate":"2023-10-31","conditions":"Metastatic Breast Cancer","enrollment":376},{"nctId":"NCT04595565","phase":"PHASE3","title":"Sacituzumab Govitecan in Primary HER2-negative Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"GBG Forschungs GmbH","startDate":"2020-10-28","conditions":"HER2-negative Breast Cancer, Triple Negative Breast Cancer","enrollment":1332},{"nctId":"NCT06889610","phase":"PHASE2","title":"A Phase II Clinical Study of Multimodal Ablation Combined With Systemic Drug Therapy for Advanced Solid Tumors.","status":"RECRUITING","sponsor":"Fudan University","startDate":"2025-11-04","conditions":"Triple Negative Breast Cancer Metastatic, Melanoma Metastatic, Colorectal Cancer Metastatic","enrollment":95},{"nctId":"NCT07156058","phase":"NA","title":"MiniPDX-based Postoperative Adjuvant Therapy for Biliary Tract Cancer","status":"RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2023-01-01","conditions":"Biliary Tract Cancer","enrollment":204},{"nctId":"NCT03755141","phase":"PHASE2","title":"Efficacy and Safety of Trastuzumab Biosimilar (Herzuma®) Plus Treatment of Physician's Choice (TPC) in Patients With HER-2 Positive Metastatic Breast Cancer","status":"COMPLETED","sponsor":"National Cancer Center, Korea","startDate":"2018-12-15","conditions":"HER2-positive Breast Cancer, Metastatic Breast Cancer","enrollment":109},{"nctId":"NCT05300958","phase":"PHASE2","title":"Deferoxamine Plus Chemotherapy for Metastatic Triple Negative Breast Cancer","status":"TERMINATED","sponsor":"Sun Yat-sen University","startDate":"2022-03-21","conditions":"Triple Negative Breast Cancer","enrollment":25},{"nctId":"NCT06954246","phase":"PHASE3","title":"A Study of MHB088C Injection Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2025-06-04","conditions":"Small Cell Lung Cancer Extensive Stage","enrollment":450},{"nctId":"NCT06584032","phase":"PHASE3","title":"Study of Fruquintinib Plus Sintilimab for Treatment of Advanced Endometrial Cancer","status":"RECRUITING","sponsor":"Hutchmed","startDate":"2024-12-12","conditions":"Advanced Endometrial Cancer","enrollment":412},{"nctId":"NCT06669611","phase":"PHASE3","title":"Nab-TPC vs GP Combined With Camrelizumab in the Treatment of Recurrent/Metastatic Nasopharyngeal Carcinoma","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-11-27","conditions":"Nasopharyngeal Cancinoma (NPC)","enrollment":242},{"nctId":"NCT06636981","phase":"PHASE2","title":"All Trans Retinoic Acid Combined with Toripalimab+Chemotherapy for Locally Advanced Inoperable or Metastatic Triple Negative Breast Cancer：a Multi-center, Multi-cohort Phase II Trial","status":"RECRUITING","sponsor":"Fudan University","startDate":"2024-11-04","conditions":"Triple Negative Breast Cancer (TNBC)","enrollment":129},{"nctId":"NCT06143553","phase":"PHASE3","title":"Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection in the Treatment of Metastatic Breast Cancer","status":"RECRUITING","sponsor":"Shanghai Yizhong Pharmaceutical Co., Ltd.","startDate":"2023-09-25","conditions":"Metastatic Breast Cancer (MBC)","enrollment":168},{"nctId":"NCT06664983","phase":"PHASE3","title":"TPC Combined With Cadonilimab VS. TPC Alone in Anti-PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-10-21","conditions":"Nasopharyngeal Cancinoma (NPC)","enrollment":84},{"nctId":"NCT03901339","phase":"PHASE3","title":"Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Participants With HR+/HER2- Metastatic Breast Cancer","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2019-05-08","conditions":"Metastatic Breast Cancer","enrollment":543},{"nctId":"NCT06641544","phase":"PHASE4","title":"The Efficacy and Safety of Different Combination Regimens of Inetetamab in First-line Treatment of HER2 Positive Metastatic Breast Cancer","status":"RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2024-10-17","conditions":"Metastatic Breast Cancer","enrollment":200},{"nctId":"NCT06561763","phase":"PHASE3","title":"TPC VS. GP Induced Chemotherapy Combined With Nimotuzumab and Toripalimab in the Treatment of Locally Advanced Nasopharyngeal Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-08-20","conditions":"High Risk Locally Advanced Nasopharyngeal Carcinoma","enrollment":416},{"nctId":"NCT06438627","phase":"PHASE3","title":"Efficacy and Safety of TPC+Apatinib+Camrelizumab vs GP+ Camrelizumab for High-Risk Nasopharyngeal Carcinoma: A Phase 3 Trial","status":"RECRUITING","sponsor":"XIANG YANQUN","startDate":"2024-05-30","conditions":"Nasopharyngeal Carcinoma","enrollment":164},{"nctId":"NCT06301165","phase":"PHASE2","title":"TPC Versus GP Induction Chemotherapy for Nasopharyngeal Carcinoma","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-03-19","conditions":"Nasopharyngeal Carcinoma","enrollment":162},{"nctId":"NCT02915744","phase":"PHASE3","title":"A Study of Etirinotecan Pegol (NKTR-102) Versus Treatment of Physician's Choice (TPC) in Patients With Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated With an Anthracycline, a Taxane, and Capecitabine","status":"COMPLETED","sponsor":"Nektar Therapeutics","startDate":"2016-11","conditions":"Metastasis, Breast Cancer","enrollment":178},{"nctId":"NCT02940925","phase":"PHASE3","title":"TPC vs PF as Induction Chemotherapy Combined With CCRT for Stage IVa-b Nasopharyngeal Carcinoma","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2016-10-20","conditions":"Nasopharyngeal Carcinoma","enrollment":241},{"nctId":"NCT05556200","phase":"PHASE2","title":"A Phase II Trial of Camrelizumab in Combination With Apatinib for Neoadjuvant Treatment of Early-stage TNBC With a High Proportion of TILs","status":"UNKNOWN","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2022-12-01","conditions":"Breast Cancer, Triple-Negative Breast Cancer","enrollment":58},{"nctId":"NCT04745975","phase":"PHASE2","title":"Guided Treatment Based on Mini-PDX in Metastatic Triple Negative Breast Cancer","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2021-02-01","conditions":"Triple Negative Breast Cancer","enrollment":100},{"nctId":"NCT02555657","phase":"PHASE3","title":"Study of Single Agent Pembrolizumab (MK-3475) Versus Single Agent Chemotherapy for Metastatic Triple Negative Breast Cancer (MK-3475-119/KEYNOTE-119)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-10-13","conditions":"Metastatic Triple Negative Breast Cancer","enrollment":622},{"nctId":"NCT01802970","phase":"PHASE1","title":"Safety and Blood Immune Cell Study of Anakinra Plus Physician's Chemotherapy Choice in Metastatic Breast Cancer Patients","status":"COMPLETED","sponsor":"Baylor Research Institute","startDate":"2012-12","conditions":"Metastatic Breast Cancer","enrollment":10},{"nctId":"NCT03055312","phase":"PHASE3","title":"Bicalutamide in Treatment of Androgen Receptor (AR) Positive Metastatic Triple Negative Breast Cancer","status":"TERMINATED","sponsor":"Sun Yat-sen University","startDate":"2016-12-20","conditions":"Metastatic Triple Negative Breast Cancer","enrollment":36},{"nctId":"NCT03801148","phase":"PHASE1","title":"A Study to Compare the Bioavailability (BA) of Dexlansoprazole Delayed-release Capsules","status":"COMPLETED","sponsor":"Takeda","startDate":"2019-01-10","conditions":"Healthy Volunteers","enrollment":122},{"nctId":"NCT03997539","phase":"PHASE2","title":"A Study of Pyrotinib Plus Vinorelbine in Comparison With Treatment of Physician's Choice in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2019-08-15","conditions":"Metastatic Breast Cancer","enrollment":256},{"nctId":"NCT03131895","phase":"PHASE1","title":"Bioequivalence Study of Dexlansoprazole Capsules From Two Manufacturing Plants","status":"COMPLETED","sponsor":"Takeda","startDate":"2017-04-25","conditions":"Healthy Volunteers","enrollment":116},{"nctId":"NCT01419197","phase":"PHASE3","title":"A Study of Trastuzumab Emtansine in Comparison With Treatment of Physician's Choice in Participants With HER2-positive Breast Cancer Who Have Received at Least Two Prior Regimens of HER2-directed Therapy","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2011-09","conditions":"Breast Cancer","enrollment":602},{"nctId":"NCT00295763","phase":"PHASE3","title":"A New Study to Follow-up Thyroid Cancer Patients Who Participated in a Previous Study, Which Compared the Success of Destruction of the Thyroid Remnant Using Standard Treatment or Thyrogen.","status":"COMPLETED","sponsor":"Genzyme, a Sanofi Company","startDate":"2006-05","conditions":"Differentiated Thyroid Cancer","enrollment":61},{"nctId":"NCT02353988","phase":"PHASE2","title":"AR-inhibitor Bicalutamide in Treating Patients With TNBC","status":"UNKNOWN","sponsor":"Jinling Hospital, China","startDate":"2015-01","conditions":"Breast Neoplasms","enrollment":60},{"nctId":"NCT00002608","phase":"PHASE2","title":"Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors","status":"COMPLETED","sponsor":"Ottawa Regional Cancer Centre","startDate":"1994-05","conditions":"Adrenocortical Carcinoma, Brain and Central Nervous System Tumors, Head and Neck Cancer","enrollment":30}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":104,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["NAB-paclitaxel, cisplatin, and capecitabine"],"phase":"phase_3","status":"active","brandName":"TPC chemotherapy","genericName":"TPC chemotherapy","companyName":"Sun Yat-sen University","companyId":"sun-yat-sen-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"TPC chemotherapy targets rapidly dividing cancer cells by interfering with their DNA replication. Used for Metastatic non-small cell lung cancer, PD-L1 positive, Metastatic triple-negative breast cancer.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}